Half-year report · HY
9776.TEDINET S100X0DA
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥380m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥338m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥390m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥708m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥343m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥389m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥344m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥251m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥464m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥222m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥256m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥226m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥16.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥16.4bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥11.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.3bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥716m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥731m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥407m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥584m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥173m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥526m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥398m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥80.4 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.35 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.87 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 67.9% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥51m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥43m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥8m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥31m |
| Clinical Testing Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥153m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥404m |
| Medical Devices And Maintenance Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥840m |
| Medical Devices And Maintenance Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥505m |
| Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥335m |
| Medical Devices And Maintenance Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥10.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥10.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥335m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥558m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥10.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥343m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥590m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥37m |
| Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥158m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥352m |
| Medical Devices And Maintenance Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥800m |
| Medical Devices And Maintenance Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥426m |
| Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| Medical Devices And Maintenance Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥507m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥545m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 533
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash dividends paid fin cf | Prior1InterimDuration | -76537000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -71741000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -398218000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -172786000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -575206000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -652209000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3966205000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2931206000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 3390999000 | JPY |
| Cash and cash equivalents | InterimInstant | 2278996000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1InterimDuration | 3280000 | JPY |
| Provision of allowance for doubtful accounts sga | InterimDuration | － | JPY |
| Directors compensations sga | Prior1InterimDuration | 65744000 | JPY |
| Directors compensations sga | InterimDuration | 69145000 | JPY |
| Salaries and allowances sga | Prior1InterimDuration | 1166701000 | JPY |
| Salaries and allowances sga | InterimDuration | 1177610000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 178484000 | JPY |
| Provision for bonuses sga | InterimDuration | 172168000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 14038000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 13702000 | JPY |
| Provision for directors retirement benefits sga | Prior1InterimDuration | 4955000 | JPY |
| Provision for directors retirement benefits sga | InterimDuration | 5159000 | JPY |
| Depreciation sga | Prior1InterimDuration | 87541000 | JPY |
| Depreciation sga | InterimDuration | 92283000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 3909865000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5607948000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 425517000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 9943332000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 53644000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 9996976000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 374945000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 374945000 | JPY |
| Transactions with other segments | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4033000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 378979000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 3909865000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5607948000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 800463000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 10318277000 | JPY |
| Net sales | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 57678000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 10375956000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 158067000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 351640000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | -2244000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 507463000 | JPY |
| Operating income | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 37124000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 544587000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 3923512000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5766507000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |